In preclinical work recently published in Nature Communications, Fred Hutchinson Cancer Center scientists used a genetic “chain reaction” to transform herpes simplex virus DNA during an HSV infection.
Wugen Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, announced it will initiate a phase II study in the first quarter of 2025 for the company’s potential first-in-class, investigational, anti-CD7 CAR T-cell therapy, WU-CART-007, in patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
FDA approved Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Tempus AI Inc. announced a collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron’s cloud-based Electronic Medical Record platform, OncoEMR, through the Molecular Profiling Integration.
Humana Inc. and Evolent Health Inc. announced an expansion of their strategic medical oncology partnership to modernize and streamline prior authorization processes to include radiation and surgical oncology services.
Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced a collaborative agreement with Thermo Fisher Scientific Inc. through its subsidiary Life Technologies Corporation.
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
As the Trump administration stands poised to redraft the nation’s public health priorities, the American Cancer Society, one of the most prominent advocates for cancer patients, finds itself in an interregnum, following an abrupt departure of its Chief Executive Officer Karen E. Knudsen.
In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment.1
When Judith O. Hopkins started medical school in 1974, she had to sign a contract promising to not get pregnant. This was not the most egregious form of sexism she would face in her career. Seeking a residency in emergency medicine in 1977, she was told point blank that she would not be considered. “I... […]
